Find a Cancer Clinical Trial for Your Child
Memorial Sloan Kettering conducts hundreds of clinical trials to improve care for people with many types of cancer. This includes more than 100 studies for children, teens, and young adults. Use this tool to browse our list of open clinical trials for young people. Each listing explains the purpose of the trial, who is eligible, and how to get more information.
New clinical trials are always opening. For more information and to find out about our latest studies, call 833-675-5437 or email us at [email protected].
Displaying 21–30 of 80 results.
-
Researchers want to find the best dose of avutometinib to treat children and young adults with advanced solid tumors. The people in this study have cancers that have spread or come back after treatment. In addition, their cancers have a mutation (change or variant) in a protein family called MAPK. These proteins tell cancer cells to grow.
-
This study aims to obtain a better understanding of the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. Together these diseases are referred to as "lymphoproliferative disorders."
-
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
-
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
-
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.